4-METHYLAMINOREX Stats & Data

4‑Methylaminorex is active in low milligram doses; use a 0.001 g scale and avoid eyeballing to prevent inadvertent overdose. The drug’s long and variable duration means redosing can cause stacking, markedly prolonging insomnia and cardiovascular strain; spacing doses by many hours and setting a pre‑planned maximum total are protective. Smoking or rapid-onset routes produce strong urges to redose; pre‑measuring total session amounts and keeping ambient temperature cool reduces binge and hyperthermia risk. Aminorex (the parent drug) was linked to pulmonary arterial hypertension (PAH), and a CHEST case series described PAH in people exposed to 4‑methylaminorex; recurrent/high‑dose use may increase PAH risk—seek evaluation for unexplained exertional dyspnea, chest pain, or syncope. MAOIs are contraindicated: combining with sympathomimetic stimulants can precipitate hypertensive crises; do not combine with linezolid, phenelzine, tranylcypromine, selegiline, or moclobemide. Animal studies show convulsions at high doses and robust dopamine release; avoid co‑administration with tramadol or high‑dose bupropion and in those with seizure history. Combining with MDMA/cathinones or other stimulants increases risks of hyperthermia, rhabdomyolysis, arrhythmia, and serotonin toxicity; stay cool, rest, and hydrate modestly (e.g., 250–500 mL/h in heat, not exceeding ~500–750 mL/h for prolonged periods). Due to look‑alike aminorex analogues (e.g., 4,4′‑DMAR) implicated in fatalities and mis‑sold products, use a trusted drug checking service when possible and avoid unknown pressed tablets. Insufflation irritates nasal mucosa; rotate nostrils, use isotonic saline, and allow tissue recovery days. Prolonged wakefulness raises psychosis risk; prioritize sleep after effects subside, using non‑alcoholic, non‑sedative sleep hygiene measures first; seek medical care for chest pain, severe headache, overheating, or confusion.